Back to Search
Start Over
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
- Source :
-
Blood Cells, Molecules & Diseases . Nov2016, Vol. 62, p49-63. 15p. - Publication Year :
- 2016
-
Abstract
- Hematological malignancies frequently express cancer-associated antigens that are shared with normal cells. Such tumor cells elude the host immune system because several T cells targeted against self-antigens are removed during thymic development, and those that persist are eliminated by a regulatory population of T cells. Chimeric antigen receptor-modified T cells (CAR-Ts) have emerged as a novel modality for tumor immunotherapy due to their powerful efficacy against tumor cells. These cells are created by transducing genes-coding fusion proteins of tumor antigen-recognition single-chain Fv connected to the intracellular signaling domains of T cell receptors, and are classed as first-, second- and third-generation, differing on the intracellular signaling domain number of T cell receptors. CAR-T treatment has emerged as a promising approach for patients with hematological malignancies, and there are several works reporting clinical trials of the use of CAR-modified T-cells in acute lymphoblastic leukemia, chronic lymphoblastic leukemia, multiple myeloma, lymphoma, and in acute myeloid leukemia by targeting different antigens. This review reports the history of adoptive immunotherapy using CAR-Ts, the CAR-T manufacturing process, and T cell therapies in development for hematological malignancies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10799796
- Volume :
- 62
- Database :
- Academic Search Index
- Journal :
- Blood Cells, Molecules & Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 119786919
- Full Text :
- https://doi.org/10.1016/j.bcmd.2016.11.001